NCT06647238

Evaluation of Pharmacist Interventions in Lipid Management for Secondary Prevention

Second Time's the Charm: Evaluation of Pharmacist Interventions in Lipid Management for Secondary Prevention

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Wake Forest University Health Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this research project is to compare the effect of pharmacist interventions versus usual care in the implementation of guideline directed lipid lowering therapies for secondary prevention.

Detailed description

Studies have shown prevention of cardiovascular adverse events is directly proportional to percent reduction in low-density lipoprotein (LDL). This evidence explains why LDL targets for secondary prevention have continued to be lowered. Cholesterol guidelines have been updated recently and encourage the use of multiple lipid lowering therapies, in addition to statins, for secondary prevention. However, these novel agents can be expensive and difficult to acquire, making prescribing challenging for providers.

Conditions

• Hyperlipidemia
• Coronary Artery Disease

Interventions

Type	Name	Description
OTHER	Pharmacist Intervention in lipid therapy	Pharmacist intervention may include but is not limited to prescribing (statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, etc.), patient education, and medication access.

Timeline

• Start date: 2024-11-05
• Primary completion: 2025-05-01
• Completion: 2025-05-27
• First posted: 2024-10-17
• Last updated: 2025-07-22
• Results posted: 2025-07-22

Locations

1 site across 1 country: United States